Anti-Diabetes Drugs - Egypt | Statista Market Forecast

The Anti-Diabetes Drugs market in Egypt is projected to witness a significant increase in revenue, with an estimated value of US$263.10m in 2024.
This growth is expected to continue at an annual growth rate (CAGR 2024-2029) of 9.32%, leading to a market volume of US$410.80m by 2029.
When compared to other countries worldwide, United States is anticipated to generate the highest revenue in this market, reaching a staggering US$37.84bn in 2024.
Egypt's demand for anti-diabetes drugs has been steadily increasing due to the rising prevalence of diabetes in the country.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Egypt has been experiencing a steady growth in recent years.

Customer preferences: Egypt has a high prevalence of diabetes, with an estimated 8.5 million people living with the disease. This has led to an increased demand for anti-diabetes drugs in the country. Additionally, the rising awareness of the importance of managing diabetes has led to more people seeking treatment.

Trends in the market: One trend in the Anti-Diabetes Drugs market in Egypt is the shift towards more affordable and accessible medications. With a large portion of the population living in poverty, many people cannot afford expensive medications. As a result, there has been a rise in the use of generic drugs in the market. Additionally, there has been an increase in the availability of over-the-counter medications, which has made it easier for people to access treatment.Another trend in the market is the increased focus on preventative measures. With the high prevalence of diabetes in Egypt, there has been a growing emphasis on preventing the disease before it develops. This has led to an increase in the use of lifestyle interventions, such as diet and exercise, as well as medications that can help prevent the onset of diabetes.

Local special circumstances: One of the unique factors affecting the Anti-Diabetes Drugs market in Egypt is the country's healthcare system. The government provides free healthcare to citizens, but the quality of care can vary widely. This has led to many people seeking private healthcare, which can be expensive. As a result, many people rely on over-the-counter medications or generic drugs to manage their diabetes.

Underlying macroeconomic factors: The Egyptian economy has been growing steadily in recent years, which has led to an increase in healthcare spending. Additionally, the government has been investing in healthcare infrastructure, which has improved access to healthcare in the country. These factors have contributed to the growth of the Anti-Diabetes Drugs market in Egypt.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.